Clinical trials: Affective Disorder
Major Depressive Disorder
The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD
Objectives: 1. To evaluate the relationship between improvement of Hamilton Depression Rating Scale (HAMD) score and basal SERT availability (binding potential) for the prognosis of MDD subjects being treated with Sertraline HCl…
- Trial name
- STAPMDDTDM (NCT02473783)
- Testing
- Sertraline HCl, I-123-ADAM SPECT
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tri-Service General Hospital (TSGH)
Major Depressive Disorder
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood.
- Trial name
- NCT01804270
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Paul E. Croarkin
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Post-traumatic Stress Disorder, Depressive Disorder
Project SERVE: Post Deployment Functioning
Functional recovery is of the utmost importance to evaluate in our returning Operation Enduring and Iraqi Freedom Veterans so that we can better understand their needs and experiences during the readjustment process from warzone…
- Conditions
- Post-traumatic Stress Disorder, Depressive Disorder, Alcoholism
- Trial name
- NCT01123642
- Where
- United States
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment Resistant Depression
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
- Trial name
- NCT03680781
- Testing
- Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Depressive Disorder, Anxiety
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a…
- Trial name
- NCT02498392
- Testing
- JNJ-42165279
- Where
- 32 sites in United States, Moldova and 4 more
- Volunteers
- 161 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder
A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs).
- Trial name
- NCT01250873
- Testing
- LY2216684, Sertraline
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Postpartum Depression (PPD)
PREPP: Preventing Postpartum Depression
The primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or…
- Trial name
- PREPP (NCT03283254)
- Testing
- Practical Resources for Effective Postpartum Parenting (PREPP), Enhanced Treatment As Usual (ETAU)
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Columbia University
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Bipolar Depression
Pediatric Bipolar Depression
The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with…
- Trial name
- NCT00811473
- Testing
- Quetiapine XR
- Where
- 48 sites in United States, Colombia and 5 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Alcohol Use Disorders, Bipolar Disorder
Zonisamide for Heavy Drinkers With Bipolar Disorder
This is a randomized, double blind, placebo controlled trial of the medication zonisamide for the purpose of reducing heavy drinking and drinking, as well as reducing mood symptoms, in bipolar subjects that drink excessively and…
- Trial name
- ZNSBP (NCT01566370)
- Testing
- Zonisamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Major Depressive Disorder, Nicotine Dependence
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
The primary purpose of this study is to determine whether, among smokers with elevated depressive symptoms, sequential antidepressant pharmacotherapy with fluoxetine (20 mg) begun 8 weeks prior to and extended throughout standard…
- Conditions
- Major Depressive Disorder, Nicotine Dependence, Depression
- Trial name
- NCT00578669
- Testing
- Fluoxetine, Dextrose
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Butler Hospital
Bipolar Disorder, Bipolar Depression
Uridine Adolescent Bipolar Depression Randomized Controlled Trial
This is a randomized, double-blind, placebo-controlled study of the investigational drug uridine as a treatment for depressed adolescents with bipolar disorder (i.e. "bipolar depression").
- Conditions
- Bipolar Disorder, Bipolar Depression, Manic Depression
- Trial name
- NCT01805440
- Testing
- Uridine
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Utah
Bipolar Disorder, Elderly
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
- Trial name
- NCT01737268
- Testing
- FK949E
- Where
- 32 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Inc
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00384033
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR), Duloxetine 60 mg/day
- Where
- 22 sites in United States
- Volunteers
- 638 people
- Sponsor
- Pfizer
Epilepsy, Schizophrenia
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
For this project we propose to refine the psychosocial intervention developed in phase one, based on input from key stakeholders, and to test the feasibility, acceptability and preliminary efficacy of the intervention.
- Conditions
- Epilepsy, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01992393
- Testing
- TIME
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Western Reserve University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.